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Arsenic is an important environmental
toxicant and carcinogen [International
Agency for Research on Cancer (IARC)
1987; National Research Council (NRC)
1999]. Chronic exposure to arsenic via
drinking water is a major health concern
throughout the world (Gebel 2000; NRC
1999). The carcinogenic effects of envi-
ronmental arsenic exposure in human pop-
ulations are well documented (IARC
1987; NRC 1999), and exposure can lead
to tumors in and toxicity of the skin, lung,
urinary bladder, liver, and other sites.
The adverse effects of arsenic are
dependent, in part, on its chemical form
and metabolism (Aposhian 1997; Vahter
2002). Humans are exposed primarily to
trivalent [arsenite, As(III)] and pentavalent
[arsenate, As(V)] inorganic arsenicals pre-
sent in the environment, as well as to
organic arsenic [e.g., dimethylarsinic acid,
DMA(V)] in some situations (Kenyon and
Hughes 2001; Shen et al. 2003b). In
mammals, As(V) is ﬁrst reduced to As(III),
whereas As(III), produced by this reduc-
tion or from direct ingestion, is methy-
lated primarily to pentavalent organic
arsenicals including monomethylarsonic
acid [MMA(V)] and DMA(V)]. MMA
and DMA are the predominant metabo-
lites of inorganic arsenic (Vahter 2002),
although DMA may be further methylated
to trimethylarsine oxide (TMAO) (Hughes
2002; Yoshida et al. 1998). The forms of
arsenic to which humans are exposed,
either directly or via metabolism, further
complicate the elucidation of their toxic
and carcinogenic mechanisms of action.
Previously, inorganic arsenicals were
thought to be more acutely toxic than
organic species, as the methylation of inor-
ganic arsenic was proposed to be a detoxi-
fication process. However, recent studies
indicate that trivalent organic arsenicals
[e.g., MMA(III) and DMA(III)] that are
metabolic products of inorganic arsenic
can be more toxic than the parent com-
pound (Petrick et al. 2001; Styblo et al.
2000). Furthermore, DMA can act as a
tumor promoter at various sites and as a
complete carcinogen for the urinary blad-
der in rats (Salim et al. 2003; Wei et al.
2002; Yamamoto et al. 1997). MMA pro-
duces preneoplastic changes in liver and
urinary bladder but does not produce
overt neoplasia (Shen et al. 2003a),
whereas TMAO can induce hepatocellular
adenomas (Shen et al. 2003b). Therefore,
it is important to compare and evaluate
the toxicity of As(III), As(V), MMA(V),
and DMA(V) under similar experimental
conditions.
Recent studies demonstrated that
arsenic acts as a co-promoter with 12-O-
tetradecanoylphorbol-13-acetate (TPA)
because together they enhance skin tumor
development in transgenic (Tg.AC) mice,
which overexpress the v-Ha-ras oncogene
(Germolec et al. 1997, 1998; Trouba et al.
2003). Because hepatic metabolism in
Tg.AC mice is not compromised by over-
expression of the v-Ha-ras oncogene
(Sanders et al. 2001), we hypothesized that
organic and inorganic arsenicals produce
similar yet distinct changes in Tg.AC liver
gene expression that may be predictive of
hepatotoxicity. The latter is important
because the liver is an important target
organ of arsenic toxicity in animals
(Waalkes et al. 2000b) and humans (Lu
et al. 2001). The liver is also a major target
organ of arsenic carcinogenicity after
in utero exposure in mice (Waalkes et al.
2003, 2004b) and in humans exposed to
environmental arsenic (Centeno et al.
2002; Zhou et al. 2002). To address the
above hypothesis, we examined the effects
of subchronic inorganic and organic
arsenical exposure on the Tg.AC mouse
liver. Our results indicate that in Tg.AC
mice, a) hepatic arsenic [e.g., As(III),
As(V), MMA(V), and DMA(V))] accumu-
lation, based on biokinetic analyses,
was dose dependent; b) global DNA
hypomethylation occurred after exposure
to As(III) As(V), MMA(V), and DMA(V);
c) pathological changes were present in the
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Previous research demonstrated that 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment
increased the number of skin papillomas in v-Ha-ras transgenic (Tg.AC) mice that had received
sodium arsenite [(As(III)] in drinking water, indicating that this model is useful for studying the
toxic effects of arsenic in vivo. Because the liver is a known target of arsenic, we examined the
pathophysiologic and molecular effects of inorganic and organic arsenical exposure on Tg.AC
mouse liver in this study. Tg.AC mice were provided drinking water containing As(III), sodium
arsenate [As(V)], monomethylarsonic acid [(MMA(V)], and 1,000 ppm dimethylarsinic acid
[DMA(V)] at dosages of 150, 200, 1,500, or 1,000 ppm as arsenic, respectively, for 17 weeks.
Control mice received unaltered water. Four weeks after initiation of arsenic treatment, TPA at a
dose of 1.25 µg/200 µL acetone was applied twice a week for 2 weeks to the shaved dorsal skin of
all mice, including the controls not receiving arsenic. In some cases arsenic exposure reduced body
weight gain and caused mortality (including moribundity). Arsenical exposure resulted in a dose-
dependent accumulation of arsenic in the liver that was unexpectedly independent of chemical
species and produced hepatic global DNA hypomethylation. cDNA microarray and reverse
transcriptase–polymerase chain reaction analysis revealed that all arsenicals altered the expression of
numerous genes associated with toxicity and cancer. However, organic arsenicals [MMA(V) and
DMA(V)] induced a pattern of gene expression dissimilar to that of inorganic arsenicals. In sum-
mary, subchronic exposure of Tg.AC mice to inorganic or organic arsenicals resulted in toxic mani-
festations, hepatic arsenic accumulation, global DNA hypomethylation, and numerous gene
expression changes. These effects may play a role in arsenic-induced hepatotoxicity and carcino-
genesis and may be of particular toxicologic relevance. Key words: arsenicals (arsenic forms), gene
expression, mouse liver, subchronic toxicity, toxicokinetics. Environ Health Perspect 112:1255–1263
(2004). doi:10.1289/txg.7152 available via http://dx.doi.org/ [Online 18 June 2004]liver after exposure to As(III), MMA(V),
and DMA(V); and d) arsenic-induced gene
expression changes, determined using
cDNA microarray and real-time reverse
transcriptase–polymerase chain reaction
(RT–PCR) analysis, occurred in the liver
of animals treated with As(III), As(V),
MMA(V), and DMA(V).
Materials and Methods
Chemicals 
As(III) and As(V) were purchased from
Aldrich Chemical Co. (Milwaukee, WI)
and Fluka Chemical Corp. (Milwaukee,
WI), respectively. MMA(V) was obtained
from AccuStandard, Inc. (New Haven,
CT). DMA(V) and TPA were purchased
from Sigma Chemical Co. (St. Louis,
MO). Customer-designed cDNA micro-
arrays (600 genes) were purchased from
BD Biosciences Clontech, Inc. (Palo Alto,
CA). [α-32P]-deoxyadenosine 5´-triphos-
phate was purchased from PerkinElmer,
Inc. (Boston, MA), and 3H-labeled
S-adenosylmethionine ([3H]-SAM) was
from Amersham (Arlington Heights, IL).
Animal Treatment
All animals were handled and treated in
compliance with the Guide for the Care
and Use of Laboratory Animals (NRC
1996). Female, homozygous Tg.AC mice
containing the fetal zeta-globin promoter
fused to the v-Ha-ras structural gene (with
mutations at codons 12 and 59) and linked
to a simian virus 40 polyadenylylation/
splice sequence were obtained from
Taconic Farms (Germantown, NY) (Leder
et al. 1990). Mice were maintained in
an animal facility at a temperature of
20–22°C, a relative humidity of 50%, and
a 12-hr light/dark cycle. Mice were ran-
domly assigned to five groups (n = 15 in
each group) and were provided unaltered
drinking water (control) and drinking
water containing As(III) (150 ppm as
arsenic), As(V) (200 ppm as arsenic),
MMA(V) (1,500 ppm as arsenic), and
DMA(V) (1,000 ppm as arsenic), respec-
tively, for 17 weeks. The doses of arsenicals
used were based on our previous studies
(Germolec et al. 1997, 1998). Multiple
doses of each arsenical were originally used
to examine papilloma development.
However, to detect gene expression
changes in the liver that may be related to
arsenic hepatotoxicity and hepatocellular
carcinogenesis, animals treated with the
maximal dose of each arsenical were
selected for analysis. 
Four weeks after initiation of arsenic
treatment, TPA at a dose of 1.25 µg/200 µL
acetone was applied twice weekly for
2 weeks to the shaved dorsal skin of all
mice, including the mice not receiving
arsenic (control). At 17 weeks the mice
were sacrificed by CO2 asphyxiation and
necropsied. Liver tissue was excised and
stored at –70°C until analysis or fixed for
histology as described below. 
During the exposure to arsenic, mortal-
ity, moribundity, clinical symptoms, body
weight, and water intake of the mice
were monitored. All mice, including those
found deceased or sacrificed as moribund,
underwent complete necropsy.
Pathological Examination
Liver samples were fixed with neutral-
buffered formalin, processed by standard
procedures, embedded in paraffin, sec-
tioned, and stained with hematoxylin and
eosin for light microscopy examination. All
pathological assessments were performed in
a blind fashion. 
Hepatic Arsenic Levels
A portion of the frozen liver (120–150 mg)
was digested in nitric acid. Total arsenic,
which would include inorganic and organic
forms, was determined using graphic
furnace atomic absorption spectrometry
(Perkin-Elmer AAnalyst100; PerkinElmer,
Inc., Norwalk, CT). Results were expressed
as micrograms arsenic per gram wet weight
liver, as reported in our recent publications
(Liu et al. 2001a; Xie et al. 2004). 
Global DNA Methylation Assay
Genomic DNA was extracted from liver
tissue and purified using DNeasy Kits
(Qiagen, Valencia, CA). Global DNA
methylation status was assessed by methyl
acceptance assay (Chen et al. 2004). Brieﬂy,
DNA (1 µg) was incubated at 37°C for 2 hr
in a 30-µL mixture containing 1.25 µM
(3 µCi) [3H]-SAM, 4 units CpG methylase
(M. Sss I) (New England Biolabs, Inc.,
Beverly, MA), 10 mM DDT, Tris-EDTA
buffer (100 mM Tris, 10 mM EDTA,
pH 8.0), and 100 mM NaCl. The reaction
was terminated on ice and transferred onto
a Whatman DE81 filter (Whatman
International Ltd., Maidstone, U.K.). The
filter was washed on a vacuum filtration
apparatus with 2 mL 0.5 M phosphate
buffer (pH 7.0) 5 times, followed by a
wash with 2 mL 70% ethanol and 2 mL
absolute ethanol. After the ﬁlter was dried,
the bound radioactivity was measured
by scintillation (Beckman LS 6500
Scintillation Counter; Beckman Coulter,
Inc., Fullerton, CA). 
cDNA Microarray Analysis
Microarray analysis was performed as
previously described (Xie et al. 2004).
Brieﬂy, total RNA was extracted from liver
tissues with Trizol reagent and puriﬁed with
RNeasy columns (Qiagen). Five micro-
grams pooled RNA (n = 5) was converted
to [α-32P]-dATP–labeled cDNA probe
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Table 1. Mortality due to arsenical exposure.a
Arsenical No. Found dead Sacriﬁced moribund Total (%)b
Control 15 0 0 0 (0)
AS(III) (150 ppm) 15 1 2 3 (20) 
As(V) (200 ppm) 15 0 0 0 (0)
MMA(V) (1,500 ppm) 15 3 3 6 (40)*
DMA(V) (1,000 ppm) 15 2 1 3 (20)
aArsenicals (ppm as arsenic) were administered for 17 weeks in drinking water; animal health was monitored twice daily.
bTotal dead or euthanized before end of the experiment. *Statistically signiﬁcant (p < 0.05) compared with control.
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Figure 1. Change in animal body weight during exposure to arsenicals.with Atlas speciﬁc cDNA synthesis primers
(BD Biosciences Clontech Inc.). The probe
was purified with a NucleoSpin column
(BD Biosciences Clontech), denatured at
100°C for 2–3 min, and hybridized to the
membrane in triplicate with Expresshyb
buffer (BD Biosciences Clontech) at 68°C
overnight. The membranes were washed
at 68°C four times (30 min each) in
2 × sodium chloride/sodium citrate
(SSC)/1% sodium dodecyl sulfate (SDS),
twice in 0.1 × SSC/0.5% SDS, and exposed
to a phosphoimage screen. Images were
acquired by PhosphorImager Scanner
(Model Storm 860; Molecular Dynamics,
Sunnyvale, CA) and analyzed densito-
metrically using AtlasImage software
(version 2.01; Clontech). 
Real-time RT–PCR Analysis
Total RNA was reverse transcribed with
MMLV reverse transcriptase and oligodT
primers (PerkinElmer Inc.). The PCR
primers were designed with Primer Express
software and the SYBR Green DNA PCR
kit (Applied Biosystems, Foster City, CA)
was used for real-time RT–PCR analysis.
Differences in gene expression between
groups were calculated using cycle time
(Ct) values, which were normalized against
β-actin and expressed as relative increases/
decreases, setting control as 1.0. Assuming
that the Ct value is reflective of the initial
template amount (copy number) and that
there is 100% efficiency, a difference of
one cycle is equivalent to a 2-fold differ-
ence in initial copy number (Walker
2001).
Statistics
Data are expressed as mean ± SEM or as
incidence (for mortality). For comparisons
of gene expression between two groups, the
Student t test was used. For comparisons
among three or more groups, data were
analyzed using a one-way analysis of vari-
ance, followed by Duncan’s multiple range
test. The p-value was calculated by Fisher’s
exact test for incidence data. The level of
signiﬁcance was set at p < 0.05 in all cases.
Two-dimensional hierarchical cluster
analysis of microarray data (hybrid inten-
sity ratios to control values) was performed.
The results from clustered analysis were
examined by interactive graphical analysis
using TreeView software (http://rana.
lbl.gov/EisenSoftware.htm).
Results 
Clinical Symptoms 
During the 17 weeks of arsenical exposure,
several arsenic-treated mice were found
deceased or were euthanized because
of moribundity. Exposure to As(III)
(150 ppm) and DMA(V) (1,000 ppm)
resulted in 20% mortality, and exposure to
MMA(V) (1,500 ppm) resulted in 40%
mortality (Table 1). MMA(V) exposure
alone produced significant toxicity when
compared with control. In general, the
body weight in arsenic-treated groups was
lower than that in control groups. At the
end of arsenic exposure (17 weeks), body
weight was decreased by approximately 15,
8, 10, and 8% in mice treated with As(III)
(150 ppm), As(V) (200 ppm), MMA(V)
(1,500 ppm), or DMA(V) (1,000 ppm),
respectively (Figure 1). Our findings
suggest that exposure of Tg.AC mice to
these arsenicals produced mild to moderate
[for the MMA(V) group] toxicity.
Pathology
The treatment of As(III) plus TPA did not
induce liver tumor formation in Tg.AC
mice treated with arsenicals for 17 weeks
(unpublished data). However, morpho-
logic changes including inﬂammation, foci
of apoptosis and necrosis, and hepatocellu-
lar degeneration were observed in arsenic-
treated mice (Figure 2). Foci of apoptosis
and necrosis were observed in animals
treated with As(III) (150 ppm); however,
no apparent histologic alterations were
present in animals that received As(V)
(200 ppm). MMA(V) (1,500 ppm) pro-
duced inflammatory cell infiltration,
degeneration, and swelling; DMA(V)
(1,000 ppm) produced foci of inflamma-
tion and hepatocellular degeneration.
These findings indicate that subchronic
arsenical exposure produces pathological
alterations in the liver.
Hepatic Arsenic Content 
Although not detectable in livers of
controls, arsenic was found in the livers of
Toxicogenomics | Arsenicals and gene expression
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Figure 2. Hepatic pathological changes induced
by arsenicals. (A) Control; (B) As(III), 150 ppm;
(C)A s(V), 200 ppm; (D) MMA(V), 1,500 ppm;
(E) DMA(V), 1,000 ppm. Original magnification,
×200; bars = 50 µm.all treatment groups (Figure 3). Particularly
high levels of arsenic were present in
the livers of the MMA-treated group
(Figure 3A). When hepatic arsenic content
was plotted against arsenical dose, a strong
linear correlation was observed (r = 0.98)
(Figure 3B), suggesting that subchronic
arsenic exposure results in arsenic accumu-
lation in the liver that is dose dependent. 
Global DNA Methylation Status
Global DNA methylation was assessed by
methyl acceptance assay (Figure 4). This
assay uses a bacterial DNA methyltrans-
ferase that indiscriminately methylates all
unmethylated cytosines using [3H]-SAM.
Thus, higher [3H]-SAM incorporation cor-
responds to a lower degree of methylation
(i.e., hypomethylation) of cellular DNA.
The amount of unmethylated DNA from
all the arsenical-treated groups was signifi-
cantly higher (p < 0.05) than control, indi-
cating that DNA hypomethylation occurs
in the Tg.AC mouse liver after subchronic
exposure to arsenic, regardless of the chem-
ical form. When this is correlated with
actual arsenic dose, As(III) is the most
potent hypomethylating agent; MMA(V) is
the least.
Genomic Analysis by cDNA
Microarray 
Among the 600 genes examined via
microarray analysis, 70 displayed increased
or decreased expression after subchronic
arsenic exposure. The hybrid intensity
(ratio to control value) for these 70 genes
was calculated for comparison then sub-
jected to cluster analysis to compare alter-
ations in gene expression patterns related
to the type of arsenical exposure. TreeView
revealed both similar and dissimilar
changes in gene expression patterns among
the four arsenicals (Figure 5).
The most significant arsenic-induced
changes in gene expression are listed in
Table 2. Genes associated with glutathione
S-transferase (GST) function/metabolism,
stress, apoptosis, cell proliferation, and
early neoplasia are thought to be related to
arsenic toxicity (Liu et al. 2004; Trouba
et al. 2002, 2003; Xie et al. 2004) and thus
are included for comparison. For example,
all arsenicals produced increases in GSTs
(alpha, mu, pi, and theta) and fibroblast
growth factor 2, a gene related to cell pro-
liferation. A significant increase in the
expression of insulin-like growth factor
binding protein 1 (IGFBP-1) also was
found in MMA-treated mice. In general,
all of the arsenicals produced similar effects
(i.e., increase/decrease) on gene expression;
however, the degree of change was different
in some cases. 
Real-Time RT–PCR Analysis
Real-time RT–PCR analysis was performed
for selected genes in each cluster. Figure 6
shows data for some of the genes of
interest. GST-π, early growth response pro-
tein 1 (EGR-1), heme oxygenase 1 (HO-1),
c-myc, and α-fetoprotein gene expression
was enhanced after arsenical exposure.
Generally, real-time RT–PCR analysis
conﬁrmed our microarray results.
Discussion
This study demonstrated that subchronic
exposure of transgenic (Tg.AC) mice to both
inorganic and organic arsenicals through
drinking water produced various effects on
the liver, a major target organ of arsenic
toxicity and carcinogenesis (Centeno et al.
2002; NRC 1999; Waalkes et al. 2003,
2004b). Arsenic-induced toxicity was evi-
denced by an increase in moribundity and
death, a depression in body weight, hepatic
pathological changes, and significant
changes in gene expression.
An original goal of our research was to
examine the effects of inorganic and organic
arsenic on TPA-promoted skin papilloma
development in Tg.AC mice. Although
TPA was administered to all mice (includ-
ing controls that received no arsenic), the
effects of this skin tumor promoter were
not deemed critical to our analyses of liver
pathology, DNA methylation, and gene
expression. Interestingly, topical application
of TPA in some experimental models has
systemic effects; we recently found that it
promoted liver tumors initiated by transpla-
cental arsenic exposure in female mice
(Waalkes et al. 2004b). In this study epider-
mal TPA treatment resulted in no mortality
and did not affect hepatic pathology,
indicating that the biological end points/
changes measured are most likely depen-
dent on arsenical treatment alone.
Because the liver is a major target organ
of arsenic toxicity and carcinogenesis
(Waalkes et al. 2000b, 2003, 2004b), we
examined gene expression as well as patho-
logical changes in the livers of Tg.AC mice
to further explore the usefulness of this
system as an in vivo model of arsenic
carcinogenesis and toxicity. To detect gene
expression changes that may be related to
arsenic toxicity, animals treated with the
maximal dose of each arsenical were
selected for analysis. Generally, 150 ppm
As(III) produced more toxicity and more
Toxicogenomics | Xie et al.
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Figure 4. Methyl acceptance capacity of hepatic genomic DNA of mice exposed to arsenicals. 
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Figure 5. Cluster analysis of cDNA microarray data of selected genes. Data are ratio of control values: [red] ratio > 1.0; [black] ratio = 1.0; [green] ratio < 1.0.
Relative changes in gene expression compared with those of control are presented as increased (↑), decreased (↓), or no change (NC). Double arrows high-
lighted in gray indicate ratio ≥ 2. Gene names and accession numbers are from GenBank (http://www.ncbi.nlm.nih.gov/entrez/query.fci?db=nucleotide).dramatic changes in gene expression than
200 ppm As(V). Organic arsenicals at doses
[1,500 and 1,000 ppm as arsenic for
MMA(V) and DMA(V), respectively] 5-
to 10-fold higher produced toxic effects
comparable to those produced by As(III).
Although rats are tolerant to 200 ppm
MMA(V) in drinking water for 104 weeks
(Shen et al. 2003a), the mice in our study
did not tolerate MMA(V) at 1,500 ppm,
as 40% mortality (i.e., moribundity and
death) occurred in these mice over the
17-week exposure period. The dose of
DMA(V) in this study was also higher
than the doses (50 and 200 ppm) used to
induce urinary bladder tumors in rats (Wei
et al. 2002) and also exceeded the maxi-
mum tolerated dose, as it produced 20%
mortality.
In our study, promoted and nonpro-
moted, arsenic-treated Tg.AC mice did
not display direct evidence of liver tumor
formation. However, preneoplastic lesions
(e.g., cell proliferation) occur in the liver
after chronic oral arsenic exposures in sev-
eral strains of mice (Chen et al. 2004;
Shen et al. 2003a; Waalkes et al. 2000b)
and were also observed in the liver of
Tg.AC mice exposed to arsenic in this
study. Exposure to arsenic in the drinking
water resulted in a dose-dependent accu-
mulation of arsenic in the liver that was
independent of chemical form. The high-
est hepatic content, which was observed in
the high-dose (1,500 ppm) MMA(V)
group, might contribute to the high degree
of mortality (40%) in this group. The
hepatic arsenic contents in the Tg.AC
mice receiving 150 ppm As(III) and
200 ppm As(V) in this study were 1.2 and
2.0 µg/g tissue, respectively. This was less
than the arsenic content in the skin
(8.3 µg/g tissue) and much less than that
in the hair (170.2 µg/g tissue) of Tg.AC
mice exposed to 200 ppm As(III) in the
drinking water for 14 weeks in our previ-
ous study (Germolec et al. 1998), indicat-
ing that arsenic accumulation in the liver
is lower than that in the hair or skin. This
may be because liver is the major target
organ for arsenic metabolism, and arsenic
elimination generally occurs through the
bile (Gregus et al. 2000) or urine.
DNA hypomethylation occurs after
chronic arsenic exposure in cells (Zhao
et al. 1997) and also in intact animals
(Chen et al. 2004; Okoji et al. 2002). In
the present study, all arsenicals produced
significant DNA hypomethylation in the
liver, regardless of dose. Although the doses
of MMA(V) (1,500 ppm) and DMA(V)
(1,000 ppm) used in our study were much
higher than those of As(III) (150 ppm) and
As(V) (200 ppm), MMA(V) and DMA(V)
induced less hypomethylation of hepatic
DNA than As(III) and As(V). This suggests
that inorganic arsenicals are more potent
stimulators of DNA hypomethylation
compared with MMA(V) and DMA(V).
It should be noted that global DNA
hypomethylation could co-exist with
regional or individual gene hypermethyla-
tion, as arsenic-induced p53 hypermethyla-
tion has been reported (Mass and Wang
Toxicogenomics | Xie et al.
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Table 2. Effect of arsenicals on selected gene expression.a
Intensity relative to that of control
Protein/gene Accession no.b Hybrid intensity of control As (III)(150 ppm) As (V)(200 ppm) MMA (V)(1,500 ppm) DMA (V)(1,000 ppm)
GST gene
GST-alpha J03958 5,306 2.38* 2.25* 1.23* 1.17
GST-mu U24428 3,824 1.52 1.83* 1.43 1.82*
GST-pi D30687 25,368 1.40* 1.25 0.96 1.40
GST-theta-1 X98055 3,892 1.70* 1.42 1.03 1.12
Stress-related genes
HO-1 M33203 13,480 1.19 1.31* 1.31* 1.26*
EGR-1 M20157 6,356 0.88 1.59* 1.76* 1.61*
DT diaphorase U12961 2,926 1.81* 1.79* 1.28 1.79*
Cytochrome P450 IIIA25 (CYP3A25) Y11995 19,041 1.22 1.21 1.48* 1.47*
Genes related to apoptosis 
and cell proliferation
FasL U06948 2,006 0.60 0.65 0.63 0.33*
TNF receptor–associated factor 3 U21050 3,452 0.81 0.82 0.58* 0.49*
Bad L37296 3,002 0.70* 0.67* 0.81 0.92
Granzyme A M13226 2,802 0.58* 0.53* 0.42* 0.90
Proliferating cell nuclear antigen X53068 2,768 1.33* 1.21 0.99 0.96
Fibroblast growth factor 2 M30644 1,582 2.00* 2.19* 2.16* 1.80*
c-myc proto-oncogene X00195 1,981 1.18 1.11 0.93 1.71
Tumor-related genes
Alpha fetoprotein V00743 1,631 1.72* 1.63 0.88 1.28
Insulin-like growth factor binding  X81579 7,605 0.94 1.20 2.93* 1.54*
protein 1
Insulin-like growth factor 1 AF056187 1,216 0.65 0.95 0.23 0.47
aData are based on the average value of arrays run in triplicate. bAccession numbers are from GenBank (http://www.ncbi.nlm.nih.gov/entrez/query.fci?db=nucleotide). *Original hybrid
intensity is signiﬁcantly different from that of control (p < 0.05). 
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Figure 6. Real-time RT–PCR analysis of selected genes. Data are mean ± SEM (n = 5). Dosage (ppm as
arsenic) of the arsenicals: As(III), 150 ppm; As(V), 200 ppm; MMA(V), 1,500 ppm; DMA(V), 1,000 ppm.
*Statistically signiﬁcant (p < 0.05) compared with control.1997). In our recent study, we proposed
that arsenic-induced hypomethylation of
the estrogen receptor-α gene plays an
important role in hepatocellular prolifera-
tion (Chen et al. 2004; Waalkes et al.
2004a). Efforts are currently being under-
taken to examine the methylation status of
individual genes after arsenic exposure.
DNA hypomethylation is an important
mechanism involved in aberrant gene
expression and carcinogenesis (Baylin et al.
1998; Goodman and Watson 2002). In par-
ticular, it is thought that aberrant DNA
methylation is central to the development of
liver cancers (Goodman and Watson 2002)
and is an epigenetic mechanism that under-
lines the aberrant expression of genes
involved in mouse liver carcinogenesis
(Counts et al. 1997). In the present study,
As(III), As(V), MMA(V), and DMA(V)
produced variable gene expression changes,
accounting for approximately 10% of genes
on the array. We focused primarily on a few
categories, for example, glutathione (GSH)-,
apoptosis-, and cell proliferation–related
genes, and genes important for tumor devel-
opment, as previous studies have shown
these to be related to aberrant cell growth
and neoplasia.
Glutathione systems play important
roles in arsenic toxicity and carcinogenesis
(NRC 1999; Trouba et al. 2002, 2003; Xie
et al. 2004). In the present study, the
expression of GST-µ, GST-π, GST-α, and
GST-τ was increased by all arsenicals,
although to a variable extent. GSTs are a
group of enzymes catalyzing the conjuga-
tion and oxidation of GSH with arsenic
(Xie et al. 2004). An increase in GST
expression/activity (particularly GST-π)
has been reported to play an important role
in cellular efflux of arsenic–GSH conju-
gates and to be a mechanism of arsenic tol-
erance (Brambila et al. 2002; Liu et al.
2001a; Wang et al. 1996). Increases in
GST-π positive foci have been proposed to
be a hepatic preneoplastic biomarker in
chronic arsenic-exposed populations
(Nishikawa et al. 2002; Shen et al. 2003a).
Changes in GST activity in humans also
are associated with altered arsenic metabo-
lism (Chiou et al. 1997; Marnell et al.
2003), and GST polymorphisms are
thought to be a susceptibility factor for
arsenic toxicity in humans (Marnell et al.
2003). Together, these data indicate that
increases in GST gene expression and/or
function are consistent events associated
with arsenic carcinogenicity and toxicity.
Oxidative stress is proposed to play an
important role in arsenic toxicity and car-
cinogenesis (Kitchin and Ahmad 2003; Liu
et al. 2001b; NRC 1999; Trouba et al.
2002; Xie et al. 2004). In addition to
GSTs, other biomarkers for arsenic-
induced oxidative stress such as HO-1
(Del Razo et al. 2001; Liu et al. 2001b),
EGR-1 (Liu et al. 2004; Simeonova et al.
2000), DT- diaphorase (Pi et al. 2003),
and cytochrome P450 3A25 (Liu et al.
2001b) were all increased in Tg.AC mice
after exposure to arsenicals. Evidence is
accumulating regarding the ability of
arsenicals to produce reactive oxygen
species and free radicals as measured using
electron spin response. This includes inor-
ganic As(III) and As(V) (Barchowsky et al.
1999) and organic MMA(III), DMA(III)
(Nesnow et al. 2002), and DMA(V)
(Yamanaka et al. 1990). Our data (e.g.,
gene expression changes and pathology)
lend further evidence for the presence of
oxidative stress during subchronic exposure
to arsenicals.
Arsenic induces apoptosis involved in
its mechanism of acute toxicity (NRC
1999). However, after chronic arsenic
exposure and the induction of malignant
transformation, the development of apop-
tosis resistance occurs (Brambila et al.
2002; Qu et al. 2002) and is associated
with the downregulation of apoptosis-
related genes (Brambila et al. 2002; Chen
et al. 2001a). In the present study, arsenical
exposure resulted in downregulation of
apoptosis-associated genes such as FasL,
tumor necrosis factor receptor–associated
factor 3, Bad, and granzyme A, and also
increased the expression of cell prolifera-
tion–related genes including c-myc, prolif-
erating cell nuclear antigen, and fibroblast
growth factor 2. These data are interesting
in light of evidence that apoptosis tolerance
and cell proliferation are important mecha-
nisms involved in chemical carcinogenesis
(Waalkes et al. 2000a), including arsenic.
Apoptosis tolerance also is accompanied by
cell proliferation, as seen in arsenic-trans-
formed cells (Brambila et al. 2002; Chen
et al. 2001b; Qu et al. 2002) in chronic
arsenic-exposed animals (Chen et al. 2004;
Xie et al. 2004), and in liver tumor and
nontumor tissues from mice exposed to
arsenic in utero (Liu et al. 2004; Waalkes
et al. 2003). Thus, the depression of apop-
tosis genes and the overexpression of cell
proliferation genes could be important in
arsenic toxicity and carcinogenesis. 
Liver is a major target of arsenic
carcinogenesis in transplacentally exposed
animal models (Waalkes et al., 2003) and
in arsenic-exposed humans (Centeno et al.
2002; Chen et al. 1997; Zhou et al. 2002).
The expression of α-fetoprotein (AFP), a
biomarker for hepatocellular carcinogene-
sis, was increased in transplacental arsenic-
induced hepatocellular carcinoma (HCC)
and tumor-surrounding tissues (Liu et al.
2004). In the present study, all the arseni-
cals tested increased AFP expression up to
3-fold in MMA(V)-treated mice. The
enhanced expression of AFP lends further
support that preneoplastic alterations occur
after subchronic arsenic exposure. Other
notable alterations in gene expression were
the overexpression of IGFBP-1 and sup-
pression of insulin-like growth factor 1
(IGF-1). Chronic exposure to nongeno-
toxic chemicals such as oxazepam and
Wyeth-14,643 increased the expression of
IGFBP-1 in a time-dependent manner
(Iida et al. 2003), and overexpression of
IGFBP-1 was also seen in transplacental
arsenic-induced HCC and tumor-sur-
rounding tissues (Liu et al. 2004).
Dysregulation of the IGF axis has been
implicated in liver tumor formation and
progression (Scharf et al. 2001). Thus, sub-
chronic exposure to arsenicals can produce
aberrant gene expression related to hepato-
carcinogenesis, some of which were
conﬁrmed in the present study.
In summary, this study demonstrated
that subchronic exposure to As(III), As(V),
MMA(V), and DMA(V) in the drinking
water resulted in variable toxic effects, accu-
mulation of arsenic in the liver, hepatic
global DNA hypomethylation, and alter-
ations in gene expression in Tg.AC mice.
These ﬁndings indicate that liver is a target
organ of subchronic arsenical exposure in
this model and support the idea that altered
DNA methylation and its effects on gene
expression may contribute in an epigenetic
manner to arsenic carcinogenesis. 
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